HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Change To US FDA’s Risk-Based Homeopathic Enforcement From Its OTC Monograph Overhaul

Executive Summary

Final guidance presents same descriptions of six "categories of homeopathic drug products ... potentially posing higher risks to public health” agency stated in 2019 revised draft. Agency adds reference to monograph reform in explanation of how homeopathics aren't GRASE.  

You may also be interested in...



Homeopathic Nasal Spray Firm Warned About Microbial Contamination Needs GMP Remediation

FDA advises additional recalls of Green Pharmaceuticals’ SnoreStop NasoSpray could be needed. Agency’s testing showed a batch of SnoreStop NasoSpray is adulterated because “it consists in whole or in part of any filthy, putrid, or decomposed substance.”

US Courts Reject Reinstating FDA's Homeopathic Drug Policy As Challenge To Change Proceeds

Decisions in US Circuit and District courts for District of Columba are on complaint by Rx drug firm MediNatura, but should resonate for OTC homeopathic firms as well as all businesses across the sector. MediNatura appealed district ruling rejecting request for injunction against FDA’s withdrawal of 1988 homeopathic CPG.

OTC Homeopathy Group Revises Label Disclaimers In Light Of FTC Scrutiny

American Association of Homeopathic Pharmacists says its new recommended disclaimer for product labels – saying claims are not based on accepted medical evidence – is supported by research showing the language is clear to consumers. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel